Ultragenyx Pharmaceutical Inc.
Financials
Valuation Metrics
Ultragenyx Pharmaceutical Inc.'s Market Cap is $1.61B. At end of 2025 it was $2.30B. Ranked #2124 of 3,116 in US market (top 68%), #823 of 1,472 on NASDAQ (top 56%), #151 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 57%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.61B | US#2,124/3,116 Sec#151/265 |
| Revenue | $717M | US#2,065/3,116 Sec#67/265 |
| Net Income | $-586M | US—/3,116 Sec—/265 |
| Total Assets | $1.26B | US#2,349/3,116 Sec#78/265 |
| Net Assets | $-291M | US#2,993/3,116 Sec#259/265 |
| Employees | 1,371 | US#1,863/3,116 Sec#48/265 |
| Value | ||
| P/S | 2.24x | US#1,410/3,116 Sec#35/265 |
| FCF Yield | -30.46% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROA | -46.39% | US#2,970/3,116 Sec#204/265 |
| Op. Margin | -73.77% | US#2,684/3,116 Sec#114/265 |
| Revenue Growth | 17.50% | US#775/3,116 Sec#76/265 |
| Financial Health | ||
| Total Debt | $1.20B | US#1,426/3,116 Sec#41/265 |
| FCF | $-489M | US#2,902/3,116 Sec#252/265 |
| Cash | $125M | US#2,064/3,116 Sec#152/265 |
| Current Ratio | 1.73x | US#1,440/3,116 Sec#229/265 |
| Performance | ||
| 1Y Return | -52.85% | US#2,897/3,116 Sec#239/265 |
| 1M Return | 7.19% | US#773/3,116 Sec#57/265 |
| From 52W High | -59.10% | US#2,838/3,116 Sec#223/265 |
| 1Y MDD | -64.75% | US#2,841/3,116 Sec#221/265 |
| Trading | ||
| Volume | 2,721,756 shares | US#732/3,116 Sec#64/265 |
| Trading Value | $44M | US#1,401/3,116 Sec#104/265 |
| Per Share | ||
| EPS | $-5.95 | US—/3,116 Sec—/265 |
| BPS | $-2.95 | US—/3,116 Sec—/265 |
Company Info
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.